(UroToday.com) In this presentation, Dr. Christian Pfister presented results of the GETUG/AFU VESPER V05 phase III clinical trial, which compared dose-dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin (ddMVAC) versus Gemcitabine and Cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC). The standard of care for MIBC in 2021 is radical cystectomy with perioperative chemotherapy, however, to date, there is no randomized phase 3 clinical trial data to define the optimal perioperative chemotherapy regimen. Level 1 evidence supports the use of neoadjuvant chemotherapy. Lower level evidence exists for adjuvant chemotherapy, but nevertheless, it is frequently used. GC and ddMVAC are the two peri-operative chemotherapy regimens with the strongest data. The GETUG/AFU VESPER V05 trial sought to determine the optimal perioperative chemotherapy regimen.